ATE423547T1 - N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform - Google Patents

N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform

Info

Publication number
ATE423547T1
ATE423547T1 AT97945550T AT97945550T ATE423547T1 AT E423547 T1 ATE423547 T1 AT E423547T1 AT 97945550 T AT97945550 T AT 97945550T AT 97945550 T AT97945550 T AT 97945550T AT E423547 T1 ATE423547 T1 AT E423547T1
Authority
AT
Austria
Prior art keywords
phosphatidylethanolamine
acyl
active ingredient
liposome form
ingredient dosage
Prior art date
Application number
AT97945550T
Other languages
English (en)
Inventor
Paul Meers
Tong Shangguan
Shaukat Ali
Andrew Janoff
Charles Pak
Original Assignee
Transave Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave Inc filed Critical Transave Inc
Application granted granted Critical
Publication of ATE423547T1 publication Critical patent/ATE423547T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AT97945550T 1996-10-15 1997-10-15 N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform ATE423547T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2855796P 1996-10-15 1996-10-15

Publications (1)

Publication Number Publication Date
ATE423547T1 true ATE423547T1 (de) 2009-03-15

Family

ID=21844115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97945550T ATE423547T1 (de) 1996-10-15 1997-10-15 N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform

Country Status (13)

Country Link
US (2) US6120797A (de)
EP (1) EP0966267B1 (de)
AT (1) ATE423547T1 (de)
AU (1) AU725257B2 (de)
CA (1) CA2276269C (de)
DE (1) DE69739277D1 (de)
ES (1) ES2321769T3 (de)
HU (1) HUP0000522A3 (de)
IL (1) IL130822A (de)
NO (1) NO993257L (de)
NZ (2) NZ514133A (de)
SK (1) SK283760B6 (de)
WO (1) WO1998016199A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2343767T3 (es) 1997-09-18 2010-08-09 Pacira Pharmaceuticals, Inc. Composiciones anestesicas liposomicas de liberacion sostenida.
JP4575592B2 (ja) 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
WO2000003660A1 (en) 1998-07-17 2000-01-27 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
JP4198318B2 (ja) 1998-08-19 2008-12-17 ヤーゴテック アクチェンゲゼルシャフト プロポフォールの注射可能水性分散物
EP1419252A2 (de) * 2001-04-04 2004-05-19 Merrion Research I Limited Genetische analyse der peyer'schen plaques und m zellen und verfahren und zusammensetzungen zur targeting der peyer'schen plaques und m zellen
US20030096000A1 (en) * 2001-05-31 2003-05-22 Solis Rosa Maria Encapsulation of nanosuspensions in liposomes and microspheres
WO2003047499A2 (en) 2001-12-04 2003-06-12 Ben Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
EP1471885A4 (de) * 2002-01-09 2009-04-22 Transave Inc Wirkungsvolle liposom-verkapselung
US20060062839A1 (en) * 2002-01-09 2006-03-23 Elan Pharmaceuticals, Inc. Efficient liposomal encapsulation under mild conditions
WO2003059322A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
CA2475630C (en) * 2002-02-12 2011-01-18 Hunza Di Pistolesi Elvira & C. S.A.S. N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
DE60335469D1 (de) * 2002-07-02 2011-02-03 Univ Texas Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
ITMI20021455A1 (it) * 2002-07-02 2004-01-02 Ugo Raffaello Citernesi Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico
WO2005011708A1 (en) * 2003-07-31 2005-02-10 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
ITMI20041280A1 (it) * 2004-06-24 2004-09-24 Hunza Di Pistolesi Elvira & C Preparazione farmaceutiche dietetiche e-o cosmetiche per il trattamento dell'obesita' dell'alopecia della cellulite e dell'invecchiamento cutaneo
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
WO2007038619A2 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
WO2008030818A2 (en) * 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
JP2010513354A (ja) * 2006-12-19 2010-04-30 ノヴォソム アクチェンゲゼルシャフト トランスフェクションエンハンサー要素を含む脂質および脂質集合体
MX2010001684A (es) * 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
WO2010004597A1 (en) * 2008-07-08 2010-01-14 Chemi Spa Rocess for the production of n-acyl-phosphatidyl-etanolamine
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
DK2440241T3 (en) 2009-06-08 2017-10-02 Amunix Operating Inc GROWTH HORMON POLYPEPTIDES AND PROCEDURES FOR PREPARING AND USING THEREOF
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
CN106619515A (zh) 2009-08-27 2017-05-10 工业研究与发展基金会有限公司 脂质体组合物及其用途
BR112012009801A8 (pt) 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
WO2012094727A1 (en) * 2010-10-29 2012-07-19 The Governing Council Of The University Of Toronto Lipid encapsulation of surface enhanced raman scattering (sers) nanoparticles
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2822577B1 (de) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
CA2943190A1 (en) 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
JP7041673B2 (ja) * 2016-10-13 2022-03-24 カーノット， エルエルシー Ｎ－アシルエタノールアミド誘導体およびその使用
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
AU2018258070A1 (en) 2017-04-25 2019-10-24 Adjuvance Technologies, Inc. Triterpene saponin analogues
ES3052812T3 (en) 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
WO2019079160A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGS
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
AU2019378036B2 (en) 2018-11-14 2026-05-07 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
IL298815A (en) 2020-06-25 2023-02-01 Amunix Pharmaceuticals Inc Bispecific compositions targeting HER-2 and methods for their preparation and use
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
GB2627096A (en) 2021-10-14 2024-08-14 Pacira Pharmaceuticals Inc Bupivacaine multivesicular liposome formulations and uses thereof
MX2024010416A (es) 2022-03-14 2024-09-05 Pfizer Metodos de produccion de un adyuvante.
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12246092B1 (en) 2024-05-20 2025-03-11 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
CA1338702C (en) * 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents

Also Published As

Publication number Publication date
NZ336538A (en) 2001-11-30
IL130822A0 (en) 2001-07-24
DE69739277D1 (de) 2009-04-09
CA2276269C (en) 2008-09-02
WO1998016199A1 (en) 1998-04-23
ES2321769T3 (es) 2009-06-10
NO993257D0 (no) 1999-06-30
HUP0000522A1 (hu) 2000-09-28
US6120797A (en) 2000-09-19
AU725257B2 (en) 2000-10-12
AU4672397A (en) 1998-05-11
NO993257L (no) 1999-07-28
CA2276269A1 (en) 1998-04-23
NZ514133A (en) 2001-09-28
US6294191B1 (en) 2001-09-25
SK99399A3 (en) 2000-06-12
EP0966267A4 (de) 2006-02-01
SK283760B6 (sk) 2004-01-08
HUP0000522A3 (en) 2000-10-30
IL130822A (en) 2005-12-18
EP0966267A1 (de) 1999-12-29
EP0966267B1 (de) 2009-02-25

Similar Documents

Publication Publication Date Title
DE69739277D1 (de) N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
IL140710A0 (en) Pulmonary delivery of active agents
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
FI954990A0 (fi) Aktiiviainetta sisältävä transdermaalinen valmiste
FR2784294B1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
SE9704546D0 (sv) Novel compounds
DE69905170D1 (en) Thiazolopyrimidinderivate
DE60138566D1 (en) Selbstformende thermodynamisch stabile liposome
TR200001203T2 (tr) Yeni birleşik maddeler
IL128801A0 (en) Combination of no synthase inhibitors and traps of reactive forms of oxygen
TR200100366T2 (tr) Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
ES2108698T3 (es) Liposomas exentos de sustancias activas, para el tratamiento de aterosclerosis.
WO1999047101A3 (en) Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
IL139318A0 (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
ES2071995T3 (es) Composicion para la activacion de macrofagia.
ATE345778T1 (de) (ester)-lysolecithine in liposomen
BR9810433A (pt) Composições anti-helmìnticas
BR9812002A (pt) Compostos com efeito antiprimeiro-passe
SE9701184D0 (sv) Substanser för att åstadkomma preferens och skapa acceptans
GB9818445D0 (en) Medicaments
MX9705592A (es) Composiciones farmaceuticas que contienen corticosteroides y preparacion de las mismas.
ITRM980392A0 (it) Plasmide per la produzione di peptidi antimicrobici in batteri ricombinati

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties